DnB Asset Management
ROIV icon

DnB Asset Management’s Roivant Sciences ROIV Stock Holding History

DnB Asset Management’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.49M Buy
155,030
+82,010
+112% +$2.42M 0.02% 470
2026
Q1 		$2.02M Buy
73,020
+11,613
+19% +$298K 0.01% 584
2025
Q4 		$1.33M Buy
61,407
+12,576
+26% +$248K ﹤0.01% 623
2025
Q3 		$739K Sell
48,831
-5,152
-10% -$63.8K ﹤0.01% 650
2025
Q2 		$608K Buy
53,983
+5,504
+11% +$59.7K ﹤0.01% 640
2025
Q1 		$489K Buy
48,479
+3,802
+9% +$41.1K ﹤0.01% 657
2024
Q4 		$529K Sell
44,677
-7,531
-14% -$89K ﹤0.01% 660
2024
Q3 		$602K Sell
52,208
-3,814
-7% -$43.4K ﹤0.01% 650
2024
Q2 		$592K Buy
56,022
+3,386
+6% +$37.1K ﹤0.01% 643
2024
Q1 		$555K Buy
52,636
+796
+2% +$8.58K ﹤0.01% 648
2023
Q4 		$582K Buy
51,840
+5,700
+12% +$55.6K ﹤0.01% 625
2023
Q3 		$540K Sell
46,140
-11,303
-20% -$128K ﹤0.01% 632
2023
Q2 		$579K Buy
+57,443
New +$514K ﹤0.01% 627

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

DnB Asset Management's ROIV Position: Q2 2026 in Review

DnB Asset Management increased its Roivant Sciences (ROIV) stake by 112% in Q2 2026, buying an estimated $2.42M and bringing the position to 155,030 shares worth $5.49M. The position accounts for 0.02% of the portfolio, ranked #470.

DnB Asset Management first reported a position in ROIV in Q2 2023 and has held it in 13 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • DnB Asset Management held 155,030 shares of Roivant Sciences worth $5.49M as of Q2 2026.
  • DnB Asset Management bought 82,010 Roivant Sciences shares in Q2 2026, an estimated $2.42M.
  • Roivant Sciences made up 0.02% of DnB Asset Management's portfolio in Q2 2026, its #470 holding.
  • DnB Asset Management first reported a position in Roivant Sciences in Q2 2023 and has held it in 13 quarters since.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.